Exhibit 10.2

October 18, 2017

Axovant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland

Attention:
Marianne Romeo Dinsmore

Managing Director
Axovant Sciences GmbH

Re: Non-Commercial Manufacturing Provisions of the Development, Marketing and
Supply Agreement, dated May 8, 2015, by and between Arena Pharmaceuticals GmbH
and Axovant Sciences GmbH (as successor in interest to Axovant Sciences Ltd. and
Roivant Sciences Ltd.)

Dear Mrs. Dinsmore:

Reference is hereby made to that certain Development, Marketing and Supply
Agreement, dated May 8, 2015 (the "Supply Agreement"), by and between Arena
Pharmaceuticals GmbH ("Arena") and Axovant Sciences GmbH (as successor in
interest to Axovant Sciences Ltd. and Roivant Sciences Ltd.) ("Axovant").
Capitalized terms used in this letter agreement that are not otherwise defined
shall have the meanings ascribed to such terms in the Supply Agreement.

WHEREAS, Section 2.3(c) of the Supply Agreement prohibits Axovant and its
Affiliates from purchasing from any Third Party any Compound or Product,
including, without limitation, for use in clinical trials or other development,
and Section 9.1 of the Supply Agreement discusses the ownership of intellectual
property; and

WHEREAS, the Parties desire to allow Axovant to engage Third Parties to
manufacture Compound or Product exclusively for use in clinical trials or to
conduct related development work, in each case pursuant to a Development Plan
and in accordance with this letter agreement ("Manufacturing/Development Work");

NOW, THEREFORE, the Parties agree as follows:

--------------------------------------------------------------------------------

1.
From time to time, Arena may permit Axovant to engage a Third Party to perform
Manufacturing/Development Work. Nothing in this letter agreement modifies
Section 2.2 of the Supply Agreement or permits Axovant to engage a Third Party
to manufacture Compound or Product for any other purpose, including, without
limitation, for Commercialization.

2.
If Axovant desires to engage a Third Party to perform Manufacturing/Development
Work, Axovant shall so notify Arena. Such notice shall identify the Third Party
and the Manufacturing/Development Work to be conducted by such Third Party. If
Arena consents to Axovant seeking to engage a Third Party to perform the
Manufacturing/Development Work, which consent shall be in Arena's sole
discretion, then the Parties shall amend Appendix A hereto to list such Third
Party and such Manufacturing/Development Work. Axovant shall not enter into any
agreement with a Third Party relating to Manufacturing/Development Work (each, a
"Third Party Manufacturing Agreement") without Arena's prior written approval,
which approval shall be documented as described in Section 4 below.

3.
Each Third Party Manufacturing Agreement shall provide for the following:

a.
Upon Arena's election, the Third Party Manufacturing Agreement shall be
immediately assignable by Axovant to Arena or its Affiliate (as designated by
Arena), and it shall provide that any obligations accruing prior to the date of
assignment shall remain the sole responsibility of Axovant.

b.
The Third Party must promptly notify Axovant in writing of the discovery,
identification, conception, reduction to practice or other making of any
Know-How or Patents by or on behalf of such Third Party in the course of or as a
result of activities conducted under the Third Party Manufacturing Agreement.

c.
Know-How and Patents that (a) are reasonably necessary for the development,
manufacture or Commercialization of Compound or Product, or (b) relate solely
to, or are specifically tailored for use in, the manufacture of Compound or
Product, shall be assigned to Axovant or, if Arena consents, licensed (with the
right to sublicense) to Axovant.

d.
Compound and Product shall be delivered only to such location(s) and person(s)
as instructed by Axovant.

e.
Pricing and other terms that are reasonably acceptable to Arena.

4.
Axovant shall not enter into a Third Party Manufacturing Agreement without
submitting the proposed form of final Third Party Manufacturing Agreement to
Arena and securing Arena's prior written approval, which approval shall not be
unreasonably withheld or delayed. If Arena approves the Third Party
Manufacturing Agreement, then the Parties shall amend Appendix B hereto to list
such Third Party Manufacturing Agreement.

5.
With respect to each Third Party Manufacturing Agreement that is approved by
Arena, the Parties further agree as follows:

a.
Axovant will ensure that all Manufacturing/Development Work conducted pursuant
to such Third Party Manufacturing Agreement shall be done under a Development
Plan that complies with the requirements of the Supply Agreement and includes a
description of the Manufacturing/Development Work to be done by the Third Party.

--------------------------------------------------------------------------------

b.
Axovant shall promptly notify Arena in writing of any Know-How and any Patents
developed under the Third Party Manufacturing Agreement.

c.
Axovant hereby assigns to Arena or its Affiliate (as designated by Arena)
Axovant's entire right, title and interest in and to any and all Know-How and
Patents developed under the Third Party Manufacturing Agreement that are
reasonably necessary for the development, manufacture or Commercialization of
Compound or Product (including, for clarity, such Know-How and Patents that also
relate solely to, or are specifically tailored for use in, the manufacture of
Compound or Product). All such assigned Know-How and Patents shall be deemed to
be Arena Know-How and Arena Patents, respectively.

d.
Axovant hereby grants to Arena or its Affiliate (as designated by Arena) an
exclusive, worldwide, perpetual, royalty-free, fully paid-up sublicense (with
the right to sublicense) to any Know-How or Patents assigned or licensed to
Axovant under the Third Party Manufacturing Agreement which are not assigned to
Arena or its Affiliate pursuant to subsection 5.c., for any and all uses. In
each case, such Know-How and Patents shall be deemed to be (i) Arena Know-How
and Arena Patents, respectively, if they are reasonably necessary for the
development, manufacture or Commercialization of Compound or Product; (ii)
Program Know­ How and Program Patents, respectively, if they relate solely to,
or are specifically tailored for use in, the manufacture of Compound or Product
(and are not otherwise deemed Arena-Know or Arena Patents pursuant to (i)
above); or

(iii) Manufacturing Know-How and Manufacturing Patents, if they do not fall
within the scope of (i) or (ii) above.
e.
The Third Party may only deliver Compound and Product to Arena or to Arena' s
designee, and Axovant will cause the Third Party to deliver Compound and Product
to the location(s) and person(s) based on the instructions of Arena, which
instructions may be modified from time to time.

f.
Upon receipt of notice from Arena that Arena elects assignment of a Third Party
Manufacturing Agreement, Axovant shall immediately assign to Arena or its
Affiliate (as designated by Arena) such agreement and take reasonable steps to
assist in the transition of activities to Arena.

The Parties agree to promptly execute any documents, filings or further
agreements to effect the above provisions, including relating to the assignment
or sublicense of intellectual property.

Except as expressly set forth in this letter agreement, the Supply Agreement
shall be unchanged and shall remain in full force and effect. Any breach or
default of this side letter shall be considered a breach or default of the
Supply Agreement. Any notice required or permitted under this letter agreement
shall be given in accordance with Section 15.9 of the Supply Agreement.

Please indicate the agreement of Axovant to the terms of this letter agreement
by returning the letter agreement countersigned below by an authorized
representative of Axovant.

Very truly yours,

--------------------------------------------------------------------------------

Arena Pharmaceuticals GmbH

By: /s/ Amit D. Munshi
Amit D. Munshi
Managing Director

By: /s/ Steven W. Spector
Steven W. Spector
Managing Director

Agreed:

Axovant Sciences GmbH

By: /s/ Marianne Romeo Dinsmore
Name: Marianne Romeo Dinsmore
Title: Managing Director

--------------------------------------------------------------------------------

APPENDIX A

PROPOSED THIRD PARTY MANUFACTURERS

Third Party
Name
Proposed Manufacturing/Development Work
Date Added to Appendix
 
 
 
 
 
 

APPENDIX B

APPROVED THIRD PARTY MANUFACTURING AGREEMENTS

Agreement
Effective Date
Agreement Counterparty
Name of Agreement
Date Added to Appendix